Technical Report No. 80

Data Integrity Management System for Pharmaceutical Laboratories
PDA Data Integrity Management System for Pharmaceutical Laboratories Technical Report Team

Authors and Contributors

Maryann Gribbin, Faith & Royale Consulting, (Co-Lead)
Anil Sawant, PhD, Merck Sharpe & Dohme, (Co-Lead)
Denyse Baker, Parenteral Drug Association
Peter Baker, U.S. Food and Drug Administration
Dennis E. Guilfoyle, PhD, Johnson & Johnson
Kir Henrici, Faith & Royale Consulting
Crystal Mersh, Quality Executive Partners Inc.
Raghuram Pannala, PhD, Sciegen Pharmaceuticals Inc.
Carmelo Rosa, PsyD, U.S. Food and Drug Administration
Jonathan Rose, Patheon Pharmaceutical Services
Siegfried Schmitt, PhD, PAREXEL Consulting
Ronald Tetzlaff, PhD, PAREXEL Consulting
John T. Davidson, Merck Sharpe & Dohme
Thomas Arista, U.S. Food and Drug Administration

To order this document, please visit: go.pda.org/TR80
Data Integrity Management System for Pharmaceutical Laboratories

Technical Report No. 80

© 2018 Parenteral Drug Association, Inc.
All rights reserved.
# Table of Contents

1.0 INTRODUCTION ................................................. 1

1.1 Purpose .................................................. 2

1.2 Scope .................................................. 2

2.0 GLOSSARY OF TERMS ........................................ 3

2.1 Acronyms ............................................. 6

3.0 REGULATORY TRENDS ........................................ 7

4.0 GENERAL CONSIDERATIONS FOR THE CONTROL OF DATA INTEGRITY IN THE LABORATORY ........... 9

4.1 Original Records ......................................... 9

4.2 Human Factors ......................................... 10

5.0 DATA INTEGRITY IN THE PHARMACEUTICAL MICROBIOLOGY LABORATORY ............................ 11

5.1 General Considerations and Risks ......................... 11

5.1.1 Interviewing Analysts .............................. 11

5.1.2 On-site Laboratory and Sampling Review ....... 12

5.1.3 Worksheet Review .................................. 13

5.1.4 Contract Laboratories ............................. 13

5.1.5 Equipment and Instrument Review ............. 14

5.2 Testing for Environmental Monitoring, Sterility, and Bacterial Endotoxins .................. 15

5.2.1 Environmental Monitoring Equipment ........... 15

5.2.2 Air Sampling Devices ............................. 15

5.2.3 Surface and Personnel Monitoring Equipment .......................... 16

5.2.4 Review of Sterility Test ........................... 16

5.2.5 Bacterial Endotoxin Testing ...................... 18

6.0 DATA INTEGRITY IN THE ANALYTICAL QUALITY CONTROL LABORATORY ..................................... 19

6.1 General Considerations and Risks ......................... 19

6.2 Hybrid Systems ........................................ 19

6.2.1 Associated Risks ................................... 20

6.2.2 Qualification ........................................ 20

6.3 Analytical Laboratory Computerized Systems (ALCS) .................................................. 21

6.3.1 Qualification of Computer Server and/or Virtual System ............................................. 23

6.3.2 Commercial Off-the-Shelf Software Validation for HPLC, GC, and Other Instrument Operations ............. 25

6.3.2.1 Controls for COTS Software for HPLC, GC, and Other Instrument Operations .... 26

6.3.3 Laboratory Instrument Functionality and Qualification ................................................ 26

6.3.4 Data Governance — Generating, Processing, Reporting, and Archiving ......................... 27

6.3.5 Data Generation ....................................... 27

6.3.6 Injection Sequences .............................. 28

6.3.7 Data Processing and Peak Integration .......... 29

6.3.8 Results Printing or Publishing ................... 34

6.3.9 Audit Trails ......................................... 34

6.3.9.1 System-Level Audit Trail ....................... 35

6.3.9.2 Application-Level Audit Trail ............... 36

6.3.9.3 Method Audit Trail ............................ 36

6.3.9.4 Results Audit Trail ............................ 37

6.3.9.5 Sequence Audit Trail .......................... 38

6.3.9.6 Project-Level Audit Trail ..................... 38

6.3.9.7 Injection Log .................................... 39

6.3.10 Transactional Log/System Errors ............. 39

6.3.10.1 Chromatography ............................. 39

6.3.10.2 Other Types of Equipment ................. 40

6.3.11 Common Deficiencies ............................ 41

6.4 Other Laboratory Equipment .......................... 42

6.5 Laboratory Data Management Software ............ 43

6.5.1 Controls ........................................... 43

6.5.2 Common Deficiencies that May Lead to Data Compromise ........................................... 44

6.5.3 Spreadsheet Validation ............................ 44

6.5.3.1 Spreadsheet Controls .......................... 44

6.5.3.2 Common Deficiencies in Spreadsheets ... 45

6.6 Electronic Data Governance ........................... 46

6.6.1 Data Backup and Storage ....................... 46

6.6.2 Routine Checks of Data and Multiple Equipment in the Laboratory ............................. 47

6.6.3 Communications with Chromatographic Software Vendors ........................................ 48

6.6.4 Presenting Data on Request in Electronic Format for Audits and Inspections ............... 48

7.0 RISK MANAGEMENT OF DATA GOVERNANCE SYSTEMS .................................................. 48

7.1 Risk Assessment ........................................ 48

7.2 Risk-Based Mitigation ................................... 49

8.0 HOW TO REMEDIATE BREACHES IN DATA INTEGRITY .................................................. 50

8.1 Discovery of Data Integrity Issues in Pharmaceutical Laboratories ........................................ 50

8.2 Investigation Considerations ........................... 50

8.3 Comprehensive Assessment of Systems ............ 51

8.4 Corrective and Preventive Action Plans ............. 52

9.0 CONCLUSION ............................................. 53

10.0 REFERENCES ............................................... 53
FIGURES AND TABLES INDEX

Figure 5.2.2-1  Misreading of EM Plates ............... 16
Figure 5.2.4-1  Membrane Location .................. 17
Figure 5.2.4-2  Hygroscopic Product ................. 17
Figure 5.2.4-3  Device Placement .................... 17
Figure 6.2-1  Data Flow in Hybrid Analytical Systems .......... 20
Figure 6.3-1  Sample Data Flow and Audit Trial Points in an ALCS .......... 23
Table 6.3.1-1  Key Terms and References for Automated Systems Requirements ... 25
Figure 6.3.5-1  Typical Data Flow in Chromatographic Analysis .......... 28
Figure 6.3.7-1  Typical Overlaid Chromatogram of Two Injections (Standard and Sample) Integrated with Same Integration Events .......... 29
Figure 6.3.7-2  Typical Chromatogram with Integration Type (Manual/Chromatographic Software) .......... 31
Figure 6.3.7-3  Chromatogram with Appropriate Integration Events .......... 31
Figure 6.3.7-4a  Chromatogram of Related Substances Analysis Presented with an Improper Scale .......... 32
Figure 6.3.7-4b  Chromatogram of Related Substances Analysis Presented with Appropriate Scale .......... 32
Figure 6.3.7-5a  Raw Data of a Single Component Analysis before Integrating .......... 32
Figure 6.3.7-5b  Raw Data Integrated with Proper Peak Width and Threshold .......... 32
Figure 6.3.7-5c  Raw Data Integrated with Improper Integration Events Leading to Peak Trimming .......... 32
Figure 6.3.7-5d  Raw Data Not Integrated Base to Base .......... 33
Figure 6.3.7-6a  Raw Data of Co-eluting Peaks of Related Substance Analysis .......... 33
Figure 6.3.7-7a  Raw Data of Multicomponent Analysis .......... 33
Figure 6.3.7-5e  Raw Data Integrated with Peak Tailing .......... 33
Figure 6.3.7-6b  Co-eluting Peaks Integrated with Suitable Peak Width and Threshold ... 33
Figure 6.3.7-7b  Multicomponent Peaks Integrated with Suitable Peak Width and Threshold .......... 33
Figure 6.3.7-5f  Raw Data Integrated Peak Followed by a Negative Peak or Drift .......... 33
Figure 6.3.7-6c  Co-eluting Peaks Integrated with Improper Integration Events, Presents Less Response .......... 33
Figure 6.3.7-7c  One Peak Integrated with Peak Trimming and another Peak by Integrating Tailing, Fronting .......... 33
Figure 6.3.9-1  Example of an Audit Trail Summary .......... 35
Figure 6.3.9-1 1  System Audit Trail (Default) .......... 36
Figure 6.3.9-1 2  System Audit Trail for Project Deletion .......... 36
Figure 6.3.9-4 1  Results Audit Trail Report .......... 37
Figure 6.3.9-4 2  Filter to Search Sample in Multiple Projects .......... 38
Figure 6.3.9-5 1  Sample Set Audit Trail Report .......... 38
Figure 6.3.9-6 1  Project Audit Trail – Deleted Injection .......... 38
Figure 6.3.10.1-1  Example of a Transactional Log .......... 39
Figure 6.3.10.1-2  Example of a System Error Log .......... 39
Figure 6.3.10.2-1  Example of a Transactional Log for XRD .......... 40
Figure 6.3.10.2-2  Example of a Transactional Log for KF .......... 41
Figure 6.5.3.1-1  Example of a Validated, Protected Spreadsheet .......... 44
Figure 6.5.3.2-1  Validated Spreadsheet: API Assay Failure (Failure Result is 96.30) .......... 45
Figure 6.5.3.2-2  Modified Standard Average Change Value in Spreadsheet for Assay Preparation 1 .......... 45
Figure 6.6-1  Typical Analytical Laboratory Data Mapping .......... 46
Table 6.6.1-1  Example of a Table in a Laboratory Manual .......... 47
Figure 6.6.2-1  Typical Data Reconciliation Exercise .......... 47
Figure 7.2-1  Risk Matrix Example for Microbiological Testing .......... 49
1.0 Introduction

A primary responsibility of pharmaceutical manufacturers is to provide safe and efficacious products of appropriate quality to patients and consumers by ensuring decisions are based on accurate, reliable, truthful, and complete data. Data integrity is a mandatory requirement and key concern of health authorities. At the time of this writing, data integrity citations, especially those related to computerized systems in laboratory and manufacturing environments, have resulted in a number of significant, well-publicized enforcement actions from the U.S. Food and Drug Administration (FDA) and other regulatory authorities, including the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA), and European Medicines Agency (EMA). These enforcement actions have taken the form of warning letters, import alerts, statements of GMP noncompliance, notices of concern, and refusals to accept and/or approve applications. Many of these actions involve failing to document or report alterations, deletions, fabrications, and/or misrepresentations of data in quality control laboratories. The range of data integrity findings spans the spectrum from unintentional errors in data reporting and lack of controls necessary to ensure data authenticity to intentional acts involving failure to report data and/or falsification of records.

The spike in enforcement actions, in part, is linked to improved detection capabilities, which have become more prevalent as technological enhancements have extended the level of automation in both pharmaceutical quality control and microbiology laboratories. The extensive use of computer systems and digital media for product testing, as well as in ancillary support systems, provides more visibility to data integrity gaps than was evident with static paper records.

The consequences of failing to uncover data integrity problems through self-discovery or internal audit programs before they are found by regulatory agency inspectors can impact the outcome of the inspection in ways that could be very damaging to a business. Similarly, the business impact on contract manufacturers, contract laboratories, and suppliers can be very serious if they fail to uncover and disclose data integrity problems before regulators or their customers’ auditors do. One of the responsibilities of regulatory agency investigators is to verify the accuracy, reliability, and integrity of data submitted in written form or other media prior to, during, or after an inspection, or as part of a drug submission for market authorization, annual report, mandatory quality defect report (e.g., Field Alert), or Adverse Event Report. The regulatory investigators (also referred to as inspectors in some regulatory regions) may detect and document inconsistencies between the information provided and available for review that may suggest data integrity problems that the company will need to correct. Such inconsistencies can be used by the health authority as the basis for a regulatory action or formal written communication. From the regulators’ perspective, noncompliance with good data integrity practices is not based solely on the intent to mislead authorities to believe that all laboratory activities are performed according to current good manufacturing practices (CGMP) when they are not. Requirements for appropriate laboratory records and documentation began with the first GMP regulations and expectations have been clarified in other publications such as the FDA Guide to Inspections of Pharmaceutical Quality Control Laboratories published in 1993 (1).

In some instances, a regulatory agency may decide to ban products from entering its jurisdiction and order or recommend that the potentially affected product be removed from the market.1 Regulatory agencies and organizations that oversee a manufacturing site’s adherence to CGMPs have made significant efforts to communicate their expectations to both industry and their inspectorates about managing data and ensuring its integrity. Some of these expectations can be found in the U.S. FDA Draft Guidance for Industry on Data Integrity and Compliance with CGMP (April 2016), World Health Organization (WHO) Guidance on Good Data and Record Management Practices (May 2016), Draft PIC/S Guidance Good Practices for Data Management and Integrity in Regulated GMP/GDP Environments (August 2016), MHRA GXP Data Integrity Definitions and Guidance (March 2018), Guidance for Industry, Part 11, Electronic Records; Electronic Signatures—Scope and Application (August 2003),

---

1 Some regulatory agencies have the legal authority to order product removal from the market, while others can only recommend such actions.
and EU Annex 11: Computerised Systems (June 2011) (2–8). Even older health authority publications on traditional audit practices may also be helpful in identifying and preventing data integrity issues in laboratories. Some examples include: FDA Guide to Inspections of Pharmaceutical Quality Control Laboratories (1) and the European Medicines Agency (EMA) Questions and Answers: Good Manufacturing Practice–Data Integrity (9).

This increased focus on data integrity by health authority investigators has resulted in the need for firms to modify and harmonize strategies to address data integrity gaps in a manner that promotes transparency, accuracy, and reliability of data as well as detection of data integrity breaches.

Industry can use technology shifts, along with the new awareness that stems from recent regulatory sanctions, to enhance their efforts to improve processes and establish mechanisms for detection and mitigation of gaps that impact data integrity in paper, hybrid, and computerized systems. The overall goal of ensuring data reliability is to protect patients as well as provide competitive sustainability.

1.1 Purpose

This technical report, developed by subject matter experts from the global pharmaceutical industry and regulatory agencies, summarizes data integrity risks and the best practices, including audit approaches, that can be utilized to develop a robust data integrity management system for laboratory settings with both manual and electronic processes that firms can follow to achieve compliance and mitigate risks. Current regulatory trends indicate breaches in data integrity and a need for additional guidance regarding the regulatory expectations. The intent of this report is to outline regulatory requirements and expectations, along with best industry practices to ensure data integrity, to highlight common gaps in laboratory data management practices, and to recommend methods of remediation.

For the purpose of this report, the term “data integrity” means the degree to which data are complete, consistent, accurate, trustworthy, and reliable and that these characteristics of the data are maintained (3) to support the quality of drug products throughout their lifecycle from the point of development through commercialization. The reliability of such data is necessary to support clinical trials, product development, manufacturing, testing, and regulatory reporting requirements, all of which are dependent on the processes and controls in place from the point of data creation to ensure data cannot be altered, deleted, omitted, or in any way modified to misrepresent what actually occurred. Data integrity is the cornerstone of establishing and maintaining confidence in the reliability of data.

1.2 Scope

This technical report focuses on the management of data integrity within pharmaceutical quality control analytical and microbiology laboratories and is also applicable to analytical development and R&D laboratories. It provides the framework and tools necessary to establish a robust data integrity management system to ensure data integrity for paper, hybrid, and computerized systems within the laboratory.